复发性喉乳头状瘤的辅助药物治疗进展  

Progress in the adjuvant therapy of the recurrent laryngeal papillomatosis

作　　者：赵晓云 魏春生 ZHAO Xiaoyun;WEI Chunsheng(Department of Otolaryngology,Eye&ENT Hospital,Fudan University,Shanghai 200031,China)

机构地区：[1]复旦大学附属眼耳鼻喉科医院耳鼻喉科,上海200031

出　　处：《中国眼耳鼻喉科杂志》2022年第3期317-320,325,共5页Chinese Journal of Ophthalmology and Otorhinolaryngology

摘　　要：喉乳头状瘤是最常见的喉部良性肿瘤,具有易复发、易侵袭、手术不易根治和恶性转化风险高的特点,临床治疗方案尚不统一。喉乳头状瘤的治疗方式包括手术治疗、辅助药物治疗、光动力治疗和疫苗接种。本文就喉乳头状瘤的辅助治疗药物干扰素、西多福韦、贝伐单抗、阿维单抗、人乳头瘤病毒疫苗、塞来昔布与埃罗替尼相关研究进行综述.Recurrent laryngeal papillomatosis(RLP)is the most common benign tumor of the larynx.There has been no identical and effective clinical therapeutic strategy for RLP due to its characteristics of recurrence,aggression,refractory,and risk of malignant transformation.The current clinical management of RLP involves surgery,adjuvant therapy,photodynamic therapy,and vaccination.This article reviews the researches on adjuvant therapy of RLP such as interferon,cidofovir,bevacizumab,avizumab,HPV vaccine,celecoxib and erotinib.

关 键 词：人乳头瘤病毒 喉乳头状瘤 西多福韦 贝伐单抗 HPV疫苗 

分 类 号：R739.65[医药卫生—肿瘤]